Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
281.19-4.07 (-1.43%)
At close: 4:00PM EDT
281.30 +0.11 (+0.04%)
After hours: 07:54PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close285.26
Open285.34
Bid278.50 x 800
Ask281.50 x 800
Day's Range278.61 - 286.00
52 Week Range223.25 - 468.55
Volume1,299,757
Avg. Volume965,220
Market Cap41.907B
Beta (5Y Monthly)0.47
PE Ratio (TTM)22.49
EPS (TTM)12.50
Earnings DateOct 20, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est397.48
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-13% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for BIIB

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Biogen Inc.
    Analyst Report: Biogen Inc.Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
    Rating
    Fair Value
    Economic Moat
    5 days agoMorningstar
View more
Advertisement
Advertisement